Logo image of UNCY

UNICYCIVE THERAPEUTICS INC (UNCY) Stock Overview

NASDAQ:UNCY - US90466Y1038 - Common Stock

4.15 USD
-0.14 (-3.26%)
Last: 9/4/2025, 11:31:01 AM

UNCY Key Statistics, Chart & Performance

Key Statistics
52 Week High11
52 Week Low3.4
Market Cap73.29M
Shares17.66M
Float17.03M
Yearly Dividend0.15
Dividend YieldN/A
EPS(TTM)-4.12
PEN/A
Fwd PE0.66
Earnings (Next)N/A N/A
IPO06-17 2021-06-17
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


UNCY short term performance overview.The bars show the price performance of UNCY in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40

UNCY long term performance overview.The bars show the price performance of UNCY in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 -40

The current stock price of UNCY is 4.15 USD. In the past month the price increased by 1.9%. In the past year, price increased by 21.15%.

UNICYCIVE THERAPEUTICS INC / UNCY Daily stock chart

UNCY Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.1 375.99B
AMGN AMGEN INC 12.95 152.01B
GILD GILEAD SCIENCES INC 14.64 140.56B
VRTX VERTEX PHARMACEUTICALS INC 23.43 101.77B
REGN REGENERON PHARMACEUTICALS 12.48 60.35B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.48B
ARGX ARGENX SE - ADR 79.6 45.16B
ONC BEONE MEDICINES LTD-ADR 6.41 37.80B
INSM INSMED INC N/A 29.89B
BNTX BIONTECH SE-ADR N/A 24.54B
NTRA NATERA INC N/A 23.00B
BIIB BIOGEN INC 8.64 20.27B

About UNCY

Company Profile

UNCY logo image Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 22 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

Company Info

UNICYCIVE THERAPEUTICS INC

4300 El Camino Real, Suite 210

Los Altos CALIFORNIA US

CEO: Shalabh Gupta

Employees: 23

UNCY Company Website

UNCY Investor Relations

Phone: 16503840642

UNICYCIVE THERAPEUTICS INC / UNCY FAQ

What is the stock price of UNICYCIVE THERAPEUTICS INC today?

The current stock price of UNCY is 4.15 USD. The price decreased by -3.26% in the last trading session.


What is the ticker symbol for UNICYCIVE THERAPEUTICS INC stock?

The exchange symbol of UNICYCIVE THERAPEUTICS INC is UNCY and it is listed on the Nasdaq exchange.


On which exchange is UNCY stock listed?

UNCY stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for UNICYCIVE THERAPEUTICS INC stock?

14 analysts have analysed UNCY and the average price target is 64.39 USD. This implies a price increase of 1451.51% is expected in the next year compared to the current price of 4.15. Check the UNICYCIVE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is UNICYCIVE THERAPEUTICS INC worth?

UNICYCIVE THERAPEUTICS INC (UNCY) has a market capitalization of 73.29M USD. This makes UNCY a Micro Cap stock.


How many employees does UNICYCIVE THERAPEUTICS INC have?

UNICYCIVE THERAPEUTICS INC (UNCY) currently has 23 employees.


What are the support and resistance levels for UNICYCIVE THERAPEUTICS INC (UNCY) stock?

UNICYCIVE THERAPEUTICS INC (UNCY) has a support level at 4.17 and a resistance level at 4.4. Check the full technical report for a detailed analysis of UNCY support and resistance levels.


Should I buy UNICYCIVE THERAPEUTICS INC (UNCY) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does UNICYCIVE THERAPEUTICS INC (UNCY) stock pay dividends?

UNCY does not pay a dividend.


What is the Price/Earnings (PE) ratio of UNICYCIVE THERAPEUTICS INC (UNCY)?

UNICYCIVE THERAPEUTICS INC (UNCY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.12).


What is the Short Interest ratio of UNICYCIVE THERAPEUTICS INC (UNCY) stock?

The outstanding short interest for UNICYCIVE THERAPEUTICS INC (UNCY) is 7.18% of its float. Check the ownership tab for more information on the UNCY short interest.


UNCY Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to UNCY. When comparing the yearly performance of all stocks, UNCY is a bad performer in the overall market: 84.31% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

UNCY Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to UNCY. UNCY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

UNCY Financial Highlights

Over the last trailing twelve months UNCY reported a non-GAAP Earnings per Share(EPS) of -4.12. The EPS increased by 62.88% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -119.44%
ROE -509%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%65.33%
Sales Q2Q%N/A
EPS 1Y (TTM)62.88%
Revenue 1Y (TTM)-100%

UNCY Forecast & Estimates

14 analysts have analysed UNCY and the average price target is 64.39 USD. This implies a price increase of 1451.51% is expected in the next year compared to the current price of 4.15.


Analysts
Analysts82.86
Price Target64.39 (1451.57%)
EPS Next Y75.77%
Revenue Next YearN/A

UNCY Ownership

Ownership
Inst Owners49.59%
Ins Owners4.93%
Short Float %7.18%
Short Ratio1.63